Mavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for Which No Targeted Medical Therapies Exist Twelve-Week Treatment with Mavacamten Demonstrated Reductions in Obstruction and Improvements in Patient...
Neuroblastoma is the most common extracranial solid cancer in children, and patients with high-risk disease are challenging to treat. In a promising development, researchers at Baylor College of Medicine released initial findings from the first two patients treated in...
– Chinese registrational clinical trial for derazantinib to begin in 2H 2019 Sinovant Sciences today announced that its Clinical Trial Application (CTA) for derazantinib has been accepted by the Center for Drug Evaluation at the China National Medical Products...
-Up to 6 patients to be enrolled in the second cohort, initial data expected in fourth quarter 2019- -Oral presentation at the Annual Meeting of the American Society of Gene and Cell Therapy- BASEL, Switzerland, April 30, 2019 (GLOBE NEWSWIRE) — Axovant Gene...
Company expects to initiate Phase 1 / 2 study ‘Unite-CNM’ in 2H2019 Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that The Medicines and Healthcare products...
Belite Bio, a drug development company targeting currently untreatable conditions in ophthalmology and metabolic diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for LBS-008...
Email
Text